GlobalData on MSN
Trials to watch: Phase III TB vaccines and MDR-TB treatments
GlobalData epidemiologists project TB cases across the 16 major markets to reach 4.5 million by 2033.
(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...
Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall ...
Federal regulators on Thursday approved a new higher-dose version of the blockbuster obesity drug Wegovy that may help users ...
A stronger version of the popular weight loss drug Wegovy is on the way after federal regulators signed off on a higher dose.
The FDA has approved a higher 7.2 mg dose of Novo Nordisk’s Wegovy (Wegovy HD) for chronic weight management in adults with ...
The FDA has approved a new higher-dose version of injectable semaglutide (Wegovy HD, Novo Nordisk) for both weight loss and ...
A University of Virginia Center for Diabetes Technology-developed algorithm – paired with a continuous glucose monitor – can ...
The FDA approved a higher 7.2 mg dose of injectable semaglutide for adults with overweight and obesity, Novo Nordisk ...
Accelerated approval of semaglutide 7.2 mg establishes a higher-dose, once-weekly GLP-1 RA option for long-term weight ...
Advancing a selective oral NMDA receptor modulator toward Phase 2a in chemotherapy-induced peripheral neuropathy following favorable Phase 1 safety and tolerability findings MIAMI, FLORIDA / ACCESS ...
CALABASAS, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results